Bruker (NASDAQ:BRKR) Stock Price Down 8.7% – Time to Sell?

Bruker Corporation (NASDAQ:BRKR)’s share price was down 8.7% on Thursday . The company traded as low as $36.15 and last traded at $36.2320. Approximately 737,200 shares traded hands during trading, a decline of 68% from the average daily volume of 2,292,505 shares. The stock had previously closed at $39.67.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BRKR shares. The Goldman Sachs Group dropped their price target on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research report on Friday, February 13th. Jefferies Financial Group set a $50.00 price target on Bruker in a research report on Thursday, February 12th. Citigroup dropped their price target on Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a research report on Friday, February 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research report on Friday, March 27th. Finally, Guggenheim dropped their price target on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $49.38.

Bruker Trading Down 10.9%

The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of -235.02, a PEG ratio of 2.40 and a beta of 1.20. The firm has a 50-day moving average of $37.34 and a 200 day moving average of $41.91.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. The firm’s revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is presently -133.33%.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 27.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Several large investors have recently modified their holdings of BRKR. Orbis Allan Gray Ltd bought a new stake in shares of Bruker during the 2nd quarter worth $192,735,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after acquiring an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Bruker by 222.6% in the fourth quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after purchasing an additional 1,269,316 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.